Choose Specialty Biosimilars Brain Cancer Breast CancerBreast Cancer CAR T-cell Therapy COVID-19 Disparities in Cancer Care Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer Genitourinary CancersGenitourinary CancersGenitourinary Cancers Global Oncology Gynecol...
参考来源: Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Ioannis V Kostopoulos, et al. Sustained MRD Negativity for Three Years Can Guide Discontinuation of Lenalidomide Maintenance after ASCT in Multiple Myeloma: Results from a Prospective Cohort Study. 2024 ASH. Abstract 361. 编辑:Baa、Quinta...
参考来源: Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Ioannis V Kostopoulos, et al. Sustained MRD Negativity for Three Years Can Guide Discontinuation of Lenalidomide Maintenance after ASCT in Multiple Myeloma: Results ...
[4] https://www.fda.gov/regulatory-information/search-fda-guidance-documents/hematologic-malignancies-regulatory-considerations-use-minimal-residual-disease-development-drug-and. [5] Jesus San-Miguel, et al. Sustained minimal ...
MULTIPLE myelomaCLINICAL trialsPROGRESSION-free survivalEXPERIMENTAL designThis document provides an overview of the importance of minimal residual disease (MRD) testing in older adults with multiple myeloma (MM). The authors explain that MRD negativity, or the absence of detectable can...
The respective rates of patients who sustained MRD negativity for at least 18 months in these arms were 42.0% and 15.0%. Meletios A. Dimopoulos, MD “These data further highlight the benefit of D-VRd and DR maintenance as a new standard of care for transplant-eligible patients with ...
enough data now. We’ve been talking about transplant here, but it doesn’t matter how you do that MRD-negativity. If you can sustain it with the maintenance that we do in the United States, I do think we ask the question on transplant now. As of right now, only high-risk patients...
Conference|International Myeloma Society Annual Meeting A new study suggests that patients with multiple myeloma who achieve sustained MRD-negativity for at least three years may be able to discontinue maintenance therapy without compromising their long-term outcomes. ...
1. Michele Cavo, Jesus San-Miguel, Saad Z Usmani,et al.Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE and MAIA. Blood.2022 Feb 10;139(6):835-844. doi:10.1182/blood.2021011101. ...
参考文献 Marion al.Early achievement of measurable residual disease negativity in the treatment of multiple myeloma as predictor of outcome.Br J Haematol . 2022 Mar 11. doi: 10.1111/bjh.18103.